https://catalyst-hm.com
America/New_York
America/New_York
America/New_York
20231105T020000
-0400
-0500
EST
20240310T020000
-0500
-0400
EDT
ai1ec-205632@catalyst-hm.com
20240329T103022Z
Online Programs
How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?
View Activity
PROGRAM CHAIR & FACULTY PRESENTER
Michael R. Grunwald, MD
Chief, Leukemia Division
Levine Cancer Institute, Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore the management of patients with newly diagnosed, relapsed/refractory, and secondary acute myeloid leukemia (AML).
EDUCATIONAL AUDIENCE
This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of AML in the Department of Veterans Affairs.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
Evaluate how genetic and molecular markers aid in determining treatment strategies for patients with AML
Personalize therapy for the treatment of newly diagnosed, relapsed/refractory (R/R), and secondary AML based on disease‐ and patient‐specific factors and communicate these treatment plans using shared decision-making strategies in the inpatient and outpatient settings
Identify adverse events associated with AML treatment to appropriately prevent and/or manage these potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care and treatment of patients with AML.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Michael R. Grunwald, MD, reports the following disclosures:
Consulting: AbbVie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gamida Cell, Gilead, Incyte, Invitae, Karius, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, Stemline
Research funding (institution): Incyte, Janssen
Stock ownership: Medtronic
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures.
Participate in the enduring activity.
Complete the online evaluation form.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
RELEASE DATE: September 7, 2021
EXPIRATION DATE: September 7, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20210907T000000
20220907T032000
0
How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner.jpg;1220;187;
ai1ec-205593@catalyst-hm.com
20240329T103022Z
Grand Rounds,Texas
Tuesday, September 7, 2021
2:00-3:00pm
Location
Houston, TX
Speaker
David Rizzieri, MD
20210907T140000
20210907T150000
Houston, TX
0
AML Grand Rounds
free
ai1ec-205599@catalyst-hm.com
20240329T103022Z
Grand Rounds,Texas
Thursday, September 23, 2021
12:00-1:00pm
Location
Temple, TX
Speaker
Alice S. Mims, MD, MSCR
20210923T120000
20210923T130000
Temple, TX
0
AML Grand Rounds
free
ai1ec-205663@catalyst-hm.com
20240329T103022Z
Online Programs
How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?
View Activity
PROGRAM CHAIR AND SPEAKING FACULTY
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Levine Cancer Institute/Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This activity will cover the assessment, monitoring, and treatment of chronic lymphocytic leukemia (CLL) in the Department of Veterans Affairs.
TARGET AUDIENCE
This educational activity is intended for community oncologists, hematologists, and clinicians involved in the assessment, monitoring, and treatment of CLL in the Department of Veterans Affairs.
LEARNING OBJECTIVES
On completing the program, attendees should be able to:
• Assess how genetic and molecular markers aid in determining treatment strategies for patients with CLL
• Evaluate the role of minimal residual disease (MRD) in monitoring the effectiveness of treatment approaches for CLL and its clinical implications
• Individualize selection of therapies for the treatment of treatment-naïve and relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate these treatment plans using shared decision-making strategies
• Recognize adverse events associated with CLL treatment to appropriately prevent and/or manage these potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with CLL.
CNE Credits: 1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/ Complete Conference Management (CCM) is accredited as a provider of continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Faculty Member
Disclosure
Ryan Jacobs, MD
Dr. Jacobs reports that he serves as a consultant for AstraZeneca, Secura Bio, Genentech, Adaptive, and TG Therapeutics. He also serves on speakers bureaus for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio and AstraZeneca. Dr. Jacobs has also completed contracted research for Pharmacyclics, Teneobio, MEI Pharma, and TG Therapeutics.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer:
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
• Marcello Morgan, MD, MPH, Medical and Scientific Services for Med Learning Group has nothing to disclose.
• Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
• Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete posttest and evaluation form online.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
RELEASE DATE: September 29, 2021
EXPIRATION DATE: September 29, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20210929T080000
20220929T090000
0
How Can You Improve Your Approaches to Care for Veterans with Chronic Lymphocytic Leukemia? Insights from the Experts
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2020/04/HM_16_01L_banner.jpg;1220;187;
ai1ec-205603@catalyst-hm.com
20240329T103022Z
Grand Rounds,Texas
Saturday, October 2, 2021
12:00-1:00pm
Location
Lubbock, TX
Speaker
Tapan M. Kadia, MD
20211002T120000
20211002T130000
Lubbock, TX
0
AML Grand Rounds
free
ai1ec-205683@catalyst-hm.com
20240329T103022Z
Online Programs
CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management
View Activity
FACULTY
Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC
Ryan Jacobs, MD
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute/Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This enduring activity will cover the treatment and management of patients with AML and CLL.
TARGET AUDIENCE
This activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with either CLL or AML
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL or AML based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with either CLL or AML treatment to appropriately prevent and/or manage potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 2.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with AML and CLL.
Credits: 2.0 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Michael R. Grunwald, MD receives consulting fees from AbbVie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gilead, Incyte, Karius, Pfizer, Premier, Sierra Oncology, and Stemline Therapeutics; receives research funding (institution) from Incyte and Janssen; and has stock ownership in Medtronic.
Ryan Jacobs, MD serves on a speaker bureau for AbbVie, AstraZeneca, Janssen, Pharmacyclics, Secura Bio and TG Therapeutics; serves as consultant for Adaptive, AstraZeneca, Genentech, Secura Bio, and TG Therapeutics; and receives research funding from MEI Pharma Pharmacyclics, Teneobio and TG Therapeutics.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group has nothing to disclose.
Deb Gordon, Medical Director for Med Learning Group, owns stock in AbbVie and Merck.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures.
Participate in the enduring activity.
Submit the evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
RELEASE DATE: November 05, 2021
EXPIRATION DATE: November 05, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20211105T015500
20221105T025500
0
CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner.jpg;1220;187;
ai1ec-205679@catalyst-hm.com
20240329T103022Z
Online Programs
How Can You Use Newer Therapies to Improve Clinical Decision-Making and Long-term Health Outcomes for Patients with Acute Myeloid Leukemia?
View Activity
PROGRAM CHAIR
David Rizzieri, MD
Senior Vice President and Director
Novant Health Cancer Institute
Charlotte, NC
SPEAKER FACULTY
Alice S. Mims, MD, MSCR
Acute Leukemia Clinical Research Director
Associate Professor of Internal Medicine
The James Comprehensive Cancer Center
The Ohio State University
Columbus, OH
PROGRAM OVERVIEW
This activity will cover the assessment, monitoring, and treatment of Acute Myeloid Leukemia (AML).
TARGET AUDIENCE
This educational activity is intended for community oncologists and advanced practice oncology clinicians involved in the assessment, monitoring, and treatment of AML.
LEARNING OBJECTIVES
On completing the program, attendees should be able to:
Evaluate how genetic and molecular markers aid in determining treatment strategies for patients with AML
Assess clinical efficacy and safety data for newer formulations and novel targeted therapies used to manage patients with AML
Personalize therapy for the treatment of newly diagnosed, relapsed/refractory (R/R), and secondary AML based on disease‐ and patient‐specific factors to communicate these treatment plans using shared decision-making strategies in the inpatient and outpatient settings
Identify adverse events associated with AML treatment to appropriately prevent and/or manage these potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved and/or interested in the assessment, monitoring, and treatment of AML.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Faculty Member
Disclosures
David Rizzieri, MD
Dr. Rizzieri reports that he serves on the speakers bureaus for Celgene, Gilead, Seattle Genetics and Stemline, Novartis, Pfizer, Sanofi, Incyte, Morphosys, BMS, Jazz, Astellas. He is also on the advisory board for AbbVie, Agios, AROG, Bayer, Celgene, Gilead, Jazz, Novartis, Pfizer, Sanofi, Seattle Genetics, Stemline, Teva, Kite, Incyte, Amgen, Acrobiotech, Cellectis, and Chimerix, Inc. Dr. Rizzieri is a consultant for AbbVie, Agios, AROG, Bayer, Celgene, Celltrion, Mustang, Pfizer, Seattle Genetics, Stemline, Kite, Incyte, Amgen, Acrobiotech, Cellectis, and Chimerix, Inc and Gilead. He has also done Data Safety Monitoring for Chimerix, Inc. and Cellectis, in addition to the UCARRT Study.
Alice S. Mims, MD, MSCR
Dr. Mims reports that she serves as a consultant for AbbVie, Genentech, Jazz Pharmaceuticals, Daiichi Saynko, BMS, and Syndax Pharmaceuticals.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer:
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Debra Gordon, MS, Medical Director for Med Learning Group has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures
Participate in the enduring activity
Complete posttest and evaluation form online.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
RELEASE DATE: November 12, 2021
EXPIRATION DATE: November 12, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20211112T172700
20221112T182700
0
How Can You Use Newer Therapies to Improve Clinical Decision-Making and Long-term Health Outcomes for Patients with Acute Myeloid Leukemia?
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2021/11/HM_22L_banner.jpg;1220;187;
ai1ec-205689@catalyst-hm.com
20240329T103022Z
Online Programs
Assessing the Growing Evidence in Alopecia Areata: The Role of JAK Inhibitors
View Activity
FACULTY
Bianca Maria Piraccini, MD (Program Chair)
Professor
Head of Division of Dermatology
Department of Experimental, Diagnostic and Specialty Medicine – DIMES
University of Bologna
Bologna, Italy
SPEAKER FACULTY
Justin M Ko, MD, MBA
Clinical Professor, Dermatology
Stanford Hospital and Clinics Lucile Packard Children’s Hospital
Stanford, California
PROGRAM OVERVIEW
This enduring activity will discuss the causes of alopecia areata and how to best manage this disease. Expert faculty will highlight the burden of alopecia areata and will offer participants strategies for implementing treatment plans that will not only address the disease itself, but also the overall health challenges for this patient population.
TARGET AUDIENCE
This educational enduring activity is intended for dermatology professionals who care for patients with alopecia areata.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
Explain the autoimmune mechanisms of current and emerging treatments for AA
Determine which patients with AA are and are not candidates for JAK inhibitors
Create treatment plans for patients with AA that address the comorbidities and psychosocial impacts of the disease
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: Education for managing alopecia areata, including current and new treatments, leads to safe practice, quality care, and continuous professional and personal development for nurses.
CNE Credits: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Faculty
Relationship
Manufacturer
Bianca Maria Piraccini, MD
Nothing to disclose
Justin M Ko, MD, MBA
Consultant
Eli Lilly & Pfizer
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela L. Davis, PhD, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures
Participate in the live virtual activity
Submit the pre- and post-test and evaluation form to Med Learning Group
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: March 02, 2022
EXPIRATION DATE: March 02, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20220302T195600
20230302T205600
0
Assessing the Growing Evidence in Alopecia Areata: The Role of JAK Inhibitors
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2022/02/h1.jpg;1220;187,medium;https://catalyst-hm.com/wp-content/uploads/2022/02/h1.jpg;1220;187,large;https://catalyst-hm.com/wp-content/uploads/2022/02/h1.jpg;1220;187,full;https://catalyst-hm.com/wp-content/uploads/2022/02/h1.jpg;1220;187
ai1ec-205722@catalyst-hm.com
20240329T103022Z
Online Programs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
View Activity
FACULTY
Ryan Jacobs, MD (PROGRAM CHAIR)
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
PROGRAM OVERVIEW
This case-based enduring activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
TARGET AUDIENCE
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/ refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Ryan Jacobs, MD reports that he serves as a consultant for AstraZeneca, Secura Bio, Genentech, Adaptive, and TG Therapeutics. He also serves on speakers’ bureaus for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio and AstraZeneca. Dr. Jacobs has also completed contracted research for Pharmacyclics, Teneobio, MEI Pharma, and TG Therapeutics.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
Debra Gordon, Medical Director of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:
Read the CME/CNE information and faculty disclosures.
Participate in the enduring activity.
Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: March 04, 2022
EXPIRATION DATE: March 04, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20220304T212700
20230304T222700
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2022/03/h_1.jpg;1220;187,medium;https://catalyst-hm.com/wp-content/uploads/2022/03/h_1.jpg;1220;187,large;https://catalyst-hm.com/wp-content/uploads/2022/03/h_1.jpg;1220;187,full;https://catalyst-hm.com/wp-content/uploads/2022/03/h_1.jpg;1220;187
ai1ec-205729@catalyst-hm.com
20240329T103022Z
Online Programs
Insights in Acute Myeloid Leukemia: Optimizing System Level Quality for Our Veterans
View Activity
PROGRAM CHAIR & FACULTY PRESENTER
Michael R. Grunwald, MD
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Associate Professor
Levine Cancer Institute, Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore the management of patients with of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, and relapsed/refractory, and secondary AML. A summary of approaches to TRAE recognition and mitigation will also be discussed.
TARGET AUDIENCE
This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of AML in the Department of Veterans Affairs.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
Evaluate the role of genetic and molecular markers in treatment options for patients with AML
Assess best practices for clinical management of newly diagnosed, and relapsed/refractory AML, as well as secondary AML, and implement shared decision-making across treatment plans
Summarize possible adverse events associated with AML treatment and understand best practices for identification and management of potential adverse events
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with acute myeloid leukemia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Grunwald has received consulting fees from AbbVie, Agios/Servier, Amgen, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gamida Cell, Gilead Sciences, Incyte Corporation, Invitae, Novartis, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, and Stemline; he has also been contracted for research with Janssen, and holds stock in Medtronic.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures.
Participate in the online activity.
Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: May 26, 2022
EXPIRATION DATE: May 26, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20220526T191700
20230526T201700
0
Insights in Acute Myeloid Leukemia: Optimizing System Level Quality for Our Veterans
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2022/05/h149n.jpg;1220;187,medium;https://catalyst-hm.com/wp-content/uploads/2022/05/h149n.jpg;1220;187,large;https://catalyst-hm.com/wp-content/uploads/2022/05/h149n.jpg;1220;187,full;https://catalyst-hm.com/wp-content/uploads/2022/05/h149n.jpg;1220;187
ai1ec-205733@catalyst-hm.com
20240329T103022Z
Online Programs
MED GAMES: Insights from the Experts—Navigating the Complex and Evolving Landscape of CLL and AML
View Activity AML and CLL Med Games Toolkit Poster Portal
Extra Resources
Video Case Study 1 Video Case Study 2
FACULTY
Michael R. Grunwald, MD
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Associate Professor
Levine Cancer Institute, Atrium Health
Charlotte, NC
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute, Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore the management of patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including the impact of molecular markers, genetic data, and patient characteristics on treatment selection; and potential adverse events of AML and CLL treatments.
TARGET AUDIENCE
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
Summarize the relevance of molecular markers and genetic data relevant to selection of therapy in CLL or AML
Review relevant treatment best practices in both newly diagnosed and relapsed/refractory AML in consideration of disease- and patient-specific factors to inform shared decision-making
Evaluate potential adverse events associated with CLL and AML therapies to implement appropriate monitoring and counseling
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with CLL and/or AML.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Michael R. Grunwald, MD, receives consulting fees from AbbVie, Agios/Servier, Amgen, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gamida Cell, Gilead Sciences, Incyte Corporation, Invitae, Karius, Novartis, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, and Stemline Therapeutics; he receives research funding (institution) from Janssen and has stock ownership in Medtronic.
Ryan Jacobs, MD, receives consulting fees from Adaptive, Genentech, MorphoSys, Secura Bio, and TG Therapeutics; he has served on the speaker’s bureau for AbbVie, AstraZeneca, Janssen, Pharmacyclics, Secura Bio, and TG Therapeutics. He has also received research funding from LOXO, MEI Pharma, Pharmacyclics, and Teneobio.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela L. Davis, PhD, Director, Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures.
Participate in the online activity.
Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Copyright ©2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity AML and CLL Med Games Toolkit Poster Portal
Extra Resources
Video Case Study 1 Video Case Study 2
20220531T131300
20230531T141300
0
MED GAMES: Insights from the Experts—Navigating the Complex and Evolving Landscape of CLL and AML
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2022/06/HM_29L_banner.jpg;1220;187,medium;https://catalyst-hm.com/wp-content/uploads/2022/06/HM_29L_banner.jpg;1220;187,large;https://catalyst-hm.com/wp-content/uploads/2022/06/HM_29L_banner.jpg;1220;187,full;https://catalyst-hm.com/wp-content/uploads/2022/06/HM_29L_banner.jpg;1220;187
ai1ec-205744@catalyst-hm.com
20240329T103022Z
Online Programs
Approaches to Improving Care in Chronic Lymphocytic Leukemia in the Veteran’s Affairs System: Insights from the Experts
View Activity
PROGRAM CHAIR & FACULTY PRESENTER
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore the management of patients with of treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This program will address approaches to individualize selection of therapy and the role of minimal residual disease (MRD) in monitoring treatment effectiveness. A summary of approaches to TRAE recognition and mitigation will also be addressed.
TARGET AUDIENCE
This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of CLL in the Department of Veterans Affairs.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
Assess how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Evaluate the role of MRD in monitoring the effectiveness of treatment approaches for CLL and its clinical implications
Individualize selection of therapies for the treatment of treatment-naïve and relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors to communicate these treatment plans using shared decision-making strategies
Recognize adverse events associated with CLL treatment to appropriately prevent and/or manage these potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Jacobs has received consulting fees from Secura Bio, Genentech, Adaptive, TG Therapeutics, and MorphoSys; he has served on the speaker’s bureau for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio, and AstraZeneca. He has also received research funding from Pharmacyclics, Teneobio, MEI Pharma, and LOXO.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures.
Participate in the online activity.
Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: July 07, 2022
EXPIRATION DATE: July 07, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20220706T180300
20230706T190300
0
Approaches to Improving Care in Chronic Lymphocytic Leukemia in the Veteran’s Affairs System: Insights from the Experts
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2022/07/h175n.jpg;1220;187,medium;https://catalyst-hm.com/wp-content/uploads/2022/07/h175n.jpg;1220;187,large;https://catalyst-hm.com/wp-content/uploads/2022/07/h175n.jpg;1220;187,full;https://catalyst-hm.com/wp-content/uploads/2022/07/h175n.jpg;1220;187
ai1ec-205749@catalyst-hm.com
20240329T103022Z
Online Programs
Optimizing the Care of Patients with Relapsed/Refractory MCL and CLL/SLL in the Veteran’s Administration System: Evaluating Evidence-Based Management
View Activity
PROGRAM CHAIR & FACULTY PRESENTER
Ryan Jacobs, MD
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute/Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore emerging treatment options and novel management strategies of patients with relapsed/refractory MCL or CLL/SLL.
TARGET AUDIENCE
This activity is designed to meet the educational needs of hematologists, oncologists, and other community-based healthcare practitioners who care for patients with MCL and CLL/SLL within the Veterans Affairs health system.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
Examine needs for immunophenotyping and evaluation of genetic data to inform CLL/SLL and MCL management in the first-line setting and beyond
Consider efficacy and safety data with emerging therapies for CLL/SLL and MCL management in consideration of current guidelines
Discuss unique mechanistic features of specific therapies, as well as adverse event profiles and the rationale for use in relapsed/refractory patients
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Ryan Jacobs, MD, receives consulting fees from Adaptive, Genentech, MorphoSys, Secura Bio, and TG Therapeutics; he has served on the speaker’s bureau for AbbVie, AstraZeneca, Janssen, Pharmacyclics, Secura Bio, and TG Therapeutics. He has also received research funding from LOXO, MEI Pharma, Pharmacyclics, and Teneobio.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
Read the CME/CNE information and faculty disclosures.
Participate in the online activity.
Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: August 03, 2022
EXPIRATION DATE: August 03, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity
20220803T173400
20230803T183400
0
Optimizing the Care of Patients with Relapsed/Refractory MCL and CLL/SLL in the Veteran’s Administration System: Evaluating Evidence-Based Management
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2022/08/f193.jpg;1220;187,medium;https://catalyst-hm.com/wp-content/uploads/2022/08/f193.jpg;1220;187,large;https://catalyst-hm.com/wp-content/uploads/2022/08/f193.jpg;1220;187,full;https://catalyst-hm.com/wp-content/uploads/2022/08/f193.jpg;1220;187
ai1ec-205907@catalyst-hm.com
20240329T103022Z
Online Programs
Updates in Acute Myeloid Leukemia: What Are Best Practices for Personalizing Therapy for Patients Within the Department of Veterans Affairs?
VIEW ACTIVITY
PROGRAM CHAIR
Courtney D. DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
PROGRAM OVERVIEW
In this enduring program, we will discuss how healthcare providers within the Department of Veterans Affairs can improve their treatment of patients with acute myeloid leukemia (AML) by providing updates on key biological features and biomarkers of AML to inform patient assessment with novel therapies. In addition, we will review the latest data on AML management and challenges in effectively communicating the rationale for therapeutic decisions with patients and caregivers.
TARGET AUDIENCE
This enduring activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with AML within the Department of Veterans Affairs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
Analyze current data concerning molecular and genetic markers to inform therapeutic decision-making in AML for patients within the Department of Veterans Affairs
Understand the latest strategies for management of newly diagnosed and relapsed/refractory AML as informed by patient-specific features for patients within the Department of Veterans Affairs
Evaluate current data concerning management of adverse events and implementation of shared decision-making to implement therapy in AML for patients within the Department of Veterans Affairs
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationship(s)
Speaker
Relationships
Manufacturer
Courtney D. DiNardo, MD
Consultant
AbbVie, Bristol Myers Squibb, Genmab, Gilead Pharmaceuticals, GlaxoSmithKline, ImmunoGen, Jazz Pharmaceuticals, Novartis, Rigel, and Servier Laboratories
Contracted Research
AbbVie, Astex, Bristol Myers Squibb, Cleave Therapeutics, Foghorn Therapuetics, Rigel Pharmaceuticals, Immune-Onc Therapeutica, Loxo Oncology, and Servier Laboratorie
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
Sylvia Hanna, Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
Emmanuella Foucault, Program Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the enduring activity at info@medlearninggroup.com
RELEASED DATE: August 02, 2023
EXPIRATION DATE: August 02, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
VIEW ACTIVITY
20230802T075300
20240802T085300
0
Updates in Acute Myeloid Leukemia: What Are Best Practices for Personalizing Therapy for Patients Within the Department of Veterans Affairs?
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_42L_banner-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_42L_banner-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_42L_banner-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_42L_banner.jpg;1220;187;
ai1ec-205901@catalyst-hm.com
20240329T103022Z
Online Programs
Improving Approaches to Care for Patients with Acute Myeloid Leukemia: Insights from the Experts to Navigate an Evolving Landscape
VIEW ACTIVITY
PROGRAM CHAIR & FACULTY PRESENTER
Michael R. Grunwald, MD, FACP
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Levine Cancer Institute, Atrium Health
Clinical Associate Professor, Wake Forest School of Medicine
Charlotte, NC
PROGRAM OVERVIEW
This enduring activity will explore the management of patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) through didactic slide review, case study discussion, and a robust Q&A session. This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, relapsed/refractory, and secondary AML. A summary of approaches to treatment-related adverse event recognition and mitigation will also be discussed.
TARGET AUDIENCE
This educational activity is intended for U.S.-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with AML.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
Appraise current data concerning molecular and genetic markers to inform therapeutic decision-making in AML
Describe the latest strategies for management of newly diagnosed and relapsed/refractory AML as informed by patient-specific features
Assess current data concerning management of adverse events and implementation of shared decision-making to implement therapy in AML
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Michael R. Grunwald, MD, FACP
Consulting fees: AbbVie, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI BioPharma, Daiichi Sankyo, Genentech, Gilead Sciences, GSK/Sierra Oncology, Incyte, Invitae, Jazz, Novartis, Ono Pharmaceutical, Pfizer, Pharmacosmos, Premier, Servier/Agios, and Stemline Therapeutics.
Research support: Incyte and Janssen.
Stock ownership: Medtronic.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Tara Nelson-Mayfield, MS, Medical Director for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Laura Aibara, Program Coordinator, for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: August 14, 2023
EXPIRATION DATE: August 14, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
VIEW ACTIVITY
20230814T150200
20240814T160200
0
Improving Approaches to Care for Patients with Acute Myeloid Leukemia: Insights from the Experts to Navigate an Evolving Landscape
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2023/08/HM_44L_banner-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2023/08/HM_44L_banner-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2023/08/HM_44L_banner-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2023/08/HM_44L_banner.jpg;1220;187;
ai1ec-205909@catalyst-hm.com
20240329T103022Z
Online Programs
Approaches to Improving Care in Chronic Lymphocytic Leukemia Patients Within the Department of Veterans Affairs: Insights from the Experts
VIEW ACTIVITY
PROGRAM CHAIR
Lori Leslie, MD
Associate Professor of Medicine
Hackensack Meridian Health School of Medicine
Director of CLL and Indolent Lymphoma
John Theurer Cancer Center
Hackensack, NJ
PROGRAM OVERVIEW
In this activity we will discuss the relevance of specific genetic and molecular markers in Chronic Lymphocytic Leukemia (CLL), review the current evidence concerning the application of minimal residual disease (MRD) monitoring, and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings. Finally, we will examine the potential adverse events associated with CLL therapeutics, including specific considerations with combination therapies.
TARGET AUDIENCE
This educational activity is intended for community hematologists, oncologists, and clinicians involved in the assessment, monitoring, and treatment of CLL for patients within the Department of Veteran Affairs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
Evaluate the relevance of specific genetic and molecular markers in CLL for patients within the Department of Veterans Affairs
Summarize current evidence concerning the application of MRD monitoring in CLL for patients within the Department of Veterans Affairs
Assess current and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings for patients within the Department of Veterans Affairs
Explain potential adverse events associated with CLL therapeutics and considerations with specific combinations for patients within the Department of Veterans Affairs
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationships
Speaker
Relationships
Manufacturer
Lori A Leslie, MD
Consultant
ADC Therapeutics, Kite Gilead, BeiGene, Pharmacyclics Inc, Merck Pharmacy, Abbvie, Genmab, SeaGen, Janssen, AstraZeneca, and Eli Lily
Speakers Bureau
Kite Gilead, Pharmacyclics, Abbvie, Genmab, SeaGen, Janssen, Eli Lily, Epizyme, TG Therapeutics, BeiGene, and AstraZeneca
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
Sylvia Hanna, Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the enduring activity at info@medlearninggroup.com
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
VIEW ACTIVITY
20230831T080000
20240831T090000
0
Approaches to Improving Care in Chronic Lymphocytic Leukemia Patients Within the Department of Veterans Affairs: Insights from the Experts
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_43L_banner_footer-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_43L_banner_footer-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_43L_banner_footer-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_43L_banner_footer.jpg;1220;187;
ai1ec-205912@catalyst-hm.com
20240329T103022Z
Online Programs
Addressing Triple-Class Refractory Veterans Affairs Patients: Treatment with Novel Mechanisms of Action – R/R Multiple Myeloma
VIEW ACTIVITY
PROGRAM CHAIR & FACULTY PRESENTER
Ken H. Young, MD, PhD
Professor and Division Director
Duke University Medical Center
Duke Cancer Center
Durham, NC
PROGRAM OVERVIEW
This enduring program focuses on relapsed/refractory multiple myeloma (R/RMM) and aims to help VA health care professionals recognize overexpressed antigens that can serve as immunologic targets on malignant multiple myeloma plasma cells and how bispecific antibodies can be leveraged as targeted therapy in R/RMM.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Veterans Affairs oncologists, hematologists, hematology pharmacists, nurse practitioners, and physician’s assistants to ensure knowledge and confidence in the management of relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
Describe the overexpressed antigens that are bispecific targets on malignant multiple myeloma plasma cells
Review the pharmacodynamics of bispecific molecules in the relapsed/refractory setting of multiple myeloma
Evaluate bispecific antibody clinical trial findings for newly approved BCMA-targeted therapy in the treatment of relapsed/refractory multiple myeloma
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Faculty Member
Relationships
Ken H. Young, MD, PhD
Dr. Young has nothing to disclose.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, VP Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
Payal Patel, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
Laura Aibara, Program Coordinator, for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the enduring activity at info@medlearninggroup.com
RELEASED DATE: September 25, 2023
EXPIRATION DATE: September 25, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
VIEW ACTIVITY
20230925T220700
20240925T230700
0
Addressing Triple-Class Refractory Veterans Affairs Patients: Treatment with Novel Mechanisms of Action – R/R Multiple Myeloma
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_47L_banner_rev-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_47L_banner_rev-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_47L_banner_rev-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2023/09/HM_47L_banner_rev.jpg;1220;187;
ai1ec-205917@catalyst-hm.com
20240329T103022Z
Online Programs
CATALYST: Optimizing Clinical Decisions in Hematologic Malignancies Through Shared Decision-Making — Focus on CLL and AML
VIEW ACTIVITY
FACULTY
Michael R. Grunwald, MD, FACP
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Levine Cancer Institute, Atrium Health
Clinical Associate Professor, Wake Forest School of Medicine
Charlotte, NC
Ryan Jacobs, MD
Clinical Director
Division of Lymphoma Therapy & Research
Department of Hematologic Oncology, BMT & Blood Disorders
Levine Cancer Institute/Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This enduring program is designed for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML and will enhance our target healthcare practitioner’s (HCP) ability to: appraise the latest molecular and genetic data in AML and CLL management; justify best practices in management of newly diagnosed relapsed/refractory AML and CLL considering specific patient-related and disease-related factors to inform management; and assess potential adverse events concerning AML and CLL to ensure optimal monitoring and management.
TARGET AUDIENCE
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.
LEARNING OBJECTIVES
After attending the meeting, participants should be better able to:
Appraise the latest molecular and genetic data in AML and CLL management
Justify best practices in management of newly diagnosed and relapsed/refractory AML and CLL considering specific patient-related and disease-related factors to inform management
Assess potential adverse events concerning AML and CLL to ensure optimal monitoring and management
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 2.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Michael R. Grunwald, MD, FACP
Consulting fees: AbbVie, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI BioPharma, Daiichi Sankyo, Genentech, Gilead Sciences, GSK/Sierra Oncology, Incyte, Invitae, Jazz, Novartis, Ono Pharmaceutical, Pfizer, Pharmacosmos, Premier, Servier/Agios, and Stemline Therapeutics.
Research support: Incyte and Janssen.
Stock ownership: Medtronic.
Ryan Jacobs, MD
Speakers bureau for AbbVie, AstraZeneca, Beigene, Janssen, Pharmacyclics and SecuraBio. Consultancy/advisory role for AbbVie, AstraZeneca, Beigene, Genentech, Janssen, SecuraBio, and Pharmacyclics. Research funding from AbbVie, AstraZeneca, LOXO Oncology, Pharmacyclics, Teneobio.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Payal Patel, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
Naomi De Brito, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: November 30, 2023
EXPIRATION DATE: November 30, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
VIEW ACTIVITY
20231130T172100
20241130T182100
0
CATALYST: Optimizing Clinical Decisions in Hematologic Malignancies Through Shared Decision-Making — Focus on CLL and AML
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2023/12/HM_49_01L_banner_footer-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2023/12/HM_49_01L_banner_footer-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2023/12/HM_49_01L_banner_footer-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2023/12/HM_49_01L_banner_footer.jpg;1906;292;